Treating auto-immune disease with platelet activating factor - opt. formulated with immunosuppressant, esp. for idiopathic thrombocytopaenic purpura

摘要

The use of PAF (platelet activating factor) antagonists (I) for treatment of autoimmune diseases, specifically idiopathic thrombocytopaenic purpura (ITP) is new. (I) is pref. a thieno(3,2-f) (1,2,4)-triazolo (4,3-a) (1,4) diazepine or (1,2,4) triazolo (4,3-a) (1,4) benzodiazepine deriv. and (II) is cyclosporin. (I) is 6-(2-chlorophenyl)-8,9-dihydro-1 -methyl-8-R-4H,7H cyclopenta (4,5) thieno (3,2-f) (1,2,4) triasolo (4,3-a) (1,4) diazepine (R = 4-morpholinylcarbonyl or dipropylaminocarbonyl) or 4-(2-chlorophenyl)-9- methyl -2-(3-(4-morpholinyl)-3-propanon-1-yl)-6H- thieno (3,2-f) (1,2,4) triazolo (4,3-a) (1,4) diazepine (Ia). USE/ADVANTAGE - (I) are effective against ITP, causing a rapid increase in the thrombocyte count, without the side effects associated with steroid therapy. Usual doses are 5-50 mg orally or 2.5-30 mg intravenously. When formulated with (II), (I) allows the dose (and thus the side effects) of (II) to be reduced.